← All companies

RAPP — Rapport Therapeutics, Inc.

Materials · Pharmaceutical Preparations · Nasdaq

CIK 0002012593 · FYE 1231 · All Form 4 filings on EDGAR ↗

Formerly: Rapport Therapeutics, Inc. (until 2026-08-26)

2Insiders filing

4Transactions

+$0Reported buys

−$3.5MReported sells

0Cluster events

Window in data: 2026-08-24 → 2026-08-25 · Data as of 2026-08-28

Insiders

Insider	Role	Txns	Reported value
Yeleswaram Krishnaswamy	Chief Development Officer	3	$2.5M
Ceesay Abraham	Chief Executive Officer	1	$938k

Transaction history

Filing date	Trade date	Ticker	Insider	Type	Shares	Price	Value	Cluster
2026-08-26	2026-08-25	RAPP	Ceesay Abraham Chief Executive Officer 10b5-1	S	18,921	$49.57	−$938k	—
2026-08-26	2026-08-25	RAPP	Yeleswaram Krishnaswamy Chief Development Officer 10b5-1	S	20,799	$50.31	−$1.0M	—
2026-08-26	2026-08-25	RAPP	Yeleswaram Krishnaswamy Chief Development Officer 10b5-1	S	16,201	$51.06	−$827k	—
2026-08-26	2026-08-24	RAPP	Yeleswaram Krishnaswamy Chief Development Officer 10b5-1	S	13,160	$50.00	−$658k	—

Known data limitations

Form 4 lag: insiders have 2 business days to file after a trade (weekends and holidays extend this), and this site re-ingests once daily — a transaction can appear here roughly three business days after it happened.
13F lag: quarterly 13F-HR holdings cover the prior quarter-end and are due 45 days after it — every institutional position shown here is at least 45 days old by construction, often more.
CUSIP→ticker gaps: 13F positions are reported by CUSIP; some holdings cannot be matched to a current ticker (delistings, corporate actions, thin metadata) and appear without one or are omitted from ticker-level views.
EDGAR timing variability: institutions file at different hours and days within their windows; amended filings (4/A, 13F-HR/A) can restate earlier periods, so historical aggregates may change between batches.

Insider Atlas is a descriptive research site, not investment advice — see the methodology for the full provenance chain.